10.16.25 -- Outsourced, In-House, Or A Combo: An Agile Recruiting Strategy Fuels Growth

In this conversation, Dr. Boro Dropulić, Executive Director of Caring Cross, shares his perspective on regional challenges, opportunities for innovation, and the role of global partnerships.

Ensure the success of your tech transfer by proactively addressing these key challenges and optimizing workflows to enable seamless scalability, compliance, and long-term operational efficiency.

Accelerate the delivery of cell and gene therapies by adopting streamlined validation and leveraging strategies that reduce timelines and support sustainable, compliant manufacturing pipelines.

Advanced therapies are evolving fast. Sponsors who harness technology and data can streamline AAV production, reduce risk, and gain a competitive edge in a rapidly shifting therapeutic landscape.

Cell and gene therapies offer curative potential, but scaling their manufacturing and delivery requires navigating complex challenges that impact consistency, compliance, and patient access worldwide.

See why it's important to partner with a CDMO that’s investing in advanced sterile fill/finish capabilities to meet the demands of complex biologics, gene therapies, and mRNA-based products.

Platform processes and strategic partnerships accelerate gene therapy development, improving consistency, and expanding patient access—laying the groundwork for a future shaped by collaboration and scalable innovation.

Review the development of a high-strength synthetic gene promoter that enhances titers while maintaining exceptional product quality and expression stability, to support more efficient biomanufacturing.

Consider how emerging gene editing technologies are advancing genetic engineering and supporting the development of new therapies through improved efficiency and control in research and clinical applications.

Explore insights into an AAV manufacturing platform designed to achieve short timelines and cost-effective scalability for producing clinical trial and commercial material in bioreactors up to 2000 L.